Galán-Ganga · Molecular biomedicine 2026 · controlled animal experiment and in vitro study · n=?

Targeted neuronal reprogramming rescues memory and neural synchrony in Alzheimer's disease.

Cited 0 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical animal model (P301S tauopathy mice) and in vitro neuronal network study

PubMed 42268557 · doi:10.1186/s43556-026-00481-w · record verified 2026-08-26

What was done

Investigated the effects of controlled, targeted, and intermittent expression of Yamanaka factors (YFs) in hippocampal neurons using in vitro GCaMP6-expressing neuronal networks and an in vivo P301S tauopathy mouse model. Adult control and P301S mice underwent neuron-specific, intermittent YF expression for six months. Evaluated endpoints included excitatory synaptic transmission, neural synchrony, cognitive and emotional behaviors, Tau pathology, epigenetic aging markers, and N-methyl-D-aspartate receptor (NMDAR) macro-complex composition and signaling.

What was found

The abstract reports qualitative directions of effect without quantitative data, sample sizes, or p-values. In neuronal networks, YF expression increased excitatory synaptic transmission and enhanced neural synchrony. In P301S mice, six months of intermittent YF induction led to sex-dependent behavioral improvements in cognitive and emotional domains, reduced Tau pathology, partially restored epigenetic aging markers, normalized NMDAR macro-complex composition and signaling (including PYK2/PTK2B), and rescued hippocampal neural synchrony.

Why it matters

Provides proof-of-concept that targeted, partial cellular reprogramming in neurons can reverse network-level and behavioral deficits in tau-driven neurodegeneration, highlighting NMDAR complex restoration as a key mediator.

Limits

The study is restricted to in vitro cultures and a transgenic P301S mouse model, which does not fully capture the complex pathology of human Alzheimer's disease. The abstract omits sample sizes, quantitative effect sizes, variance estimates, and specific details on the nature of the reported sex differences. Feasibility, translational delivery mechanisms, and safety risks (such as potential teratoma formation from in vivo reprogramming factors) were not assessed.

Cited by